PEMT Service and the creation of CMOCO: The PEMT is derived from the previous Pathology Core, which focused on banking and histological services. The banking activities of the Pathology Core are now under the new Tissue Biobanking and Processing (TBP) Shared Resource. During the past funding period, it became evident that many users need molecular testing and many had no established testing laboratory to rely on. One such client was Dr. Wells Messersmith (DT), who needed KRAS testing colon cancers to be treated with Cetuximab. Because we were able to access and annotate tissue, we decided to expand our range of services and offer KRAS testing through the Core and a newly formed clinical laboratory, the Colorado Molecular Correlates (CMOCO). We were able to quickly standardize tissue block sampling and validate a rapid turn around (ARMS/Scorpions) assay (see Franklin et al, J Mol Diag., 2010) using Cancer Center support that we could then deploy in a large multicenter trial that is ongoing. The Service continues to be opportunistic in identifying correlative testing opportunities that support the other services of the Shared Resource and the clinical research activities of Cancer Center members as indicated in the discussion of lung cancer mutation consortium below.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-27
Application #
8798605
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2016-01-31
Budget Start
2015-02-01
Budget End
2016-01-31
Support Year
27
Fiscal Year
2015
Total Cost
$188,601
Indirect Cost
$64,026
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
New, Melissa L; White, Collin M; McGonigle, Polly et al. (2018) Prostacyclin and EMT Pathway Markers for Monitoring Response to Lung Cancer Chemoprevention. Cancer Prev Res (Phila) 11:643-654
Vartuli, Rebecca L; Zhou, Hengbo; Zhang, Lingdi et al. (2018) Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation. J Clin Invest 128:2535-2550
Scott, Aaron J; Arcaroli, John J; Bagby, Stacey M et al. (2018) Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms. Mol Cancer Ther 17:2112-2122
da Silva, Raquel Frenedoso; Dhar, Deepanshi; Raina, Komal et al. (2018) Nintedanib inhibits growth of human prostate carcinoma cells by modulating both cell cycle and angiogenesis regulators. Sci Rep 8:9540
Majtan, Tomas; Jones Jr, Wendell; Krijt, Jakub et al. (2018) Enzyme Replacement Therapy Ameliorates Multiple Symptoms of Murine Homocystinuria. Mol Ther 26:834-844
Dhar, Deepanshi; Deep, Gagan; Kumar, Sushil et al. (2018) Bitter melon juice exerts its efficacy against pancreatic cancer via targeting both bulk and cancer stem cells. Mol Carcinog 57:1166-1180
Donson, Andrew M; Amani, Vladimir; Warner, Elliot A et al. (2018) Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. Mol Cancer Ther 17:1984-1994
Branchford, B R; Stalker, T J; Law, L et al. (2018) The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. J Thromb Haemost 16:352-363
Pei, Shanshan; Minhajuddin, Mohammad; Adane, Biniam et al. (2018) AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell 23:86-100.e6
Ren, Shengxiang; Rivard, Christopher J; Yu, Hui et al. (2018) A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. Clin Lung Cancer 19:450-456

Showing the most recent 10 out of 1634 publications